94 related articles for article (PubMed ID: 23128060)
21. The effectiveness of oral tin mesoporphyrin prophylaxis in reducing bilirubin production after an oral heme load in a transgenic mouse model.
DeSandre GH; Wong RJ; Morioka I; Contag CH; Stevenson DK
Biol Neonate; 2006; 89(3):139-46. PubMed ID: 16205054
[TBL] [Abstract][Full Text] [Related]
22. In vitro inhibition of heme oxygenase isoenzymes by metalloporphyrins.
Wong RJ; Vreman HJ; Schulz S; Kalish FS; Pierce NW; Stevenson DK
J Perinatol; 2011 Apr; 31 Suppl 1():S35-41. PubMed ID: 21448202
[TBL] [Abstract][Full Text] [Related]
23. New approach to prevention of kernicterus.
Cooke RW
Lancet; 1999 May; 353(9167):1814-5. PubMed ID: 10359401
[No Abstract] [Full Text] [Related]
24. Heme oxygenase in experimental intracerebral hemorrhage: the benefit of tin-mesoporphyrin.
Koeppen AH; Dickson AC; Smith J
J Neuropathol Exp Neurol; 2004 Jun; 63(6):587-97. PubMed ID: 15217087
[TBL] [Abstract][Full Text] [Related]
25. Metalloporphyrins for the treatment of neonatal jaundice.
Dennery PA
Curr Opin Pediatr; 2005 Apr; 17(2):167-9. PubMed ID: 15800405
[TBL] [Abstract][Full Text] [Related]
26. A method for interdicting the development of severe jaundice in newborns by inhibiting the production of bilirubin.
Alexander D
Pediatrics; 2004 Jan; 113(1 Pt 1):135. PubMed ID: 14702465
[No Abstract] [Full Text] [Related]
27. The role of Bach1 in the induction of heme oxygenase by tin mesoporphyrin.
Abate A; Zhao H; Wong RJ; Stevenson DK
Biochem Biophys Res Commun; 2007 Mar; 354(3):757-63. PubMed ID: 17257585
[TBL] [Abstract][Full Text] [Related]
28. Hyperbilirubinemia: current guidelines and emerging therapies.
Schwartz HP; Haberman BE; Ruddy RM
Pediatr Emerg Care; 2011 Sep; 27(9):884-9. PubMed ID: 21926893
[TBL] [Abstract][Full Text] [Related]
29. Effects of light on metalloporphyrin-treated newborn mice.
Wong RJ; Schulz S; Espadas C; Vreman HJ; Rajadas J; Stevenson DK
Acta Paediatr; 2014 May; 103(5):474-9. PubMed ID: 24417721
[TBL] [Abstract][Full Text] [Related]
30. Tin-mesoporphyrin inhibits heme oxygenase activity and heme-iron absorption in the intestine.
Böni RE; Huch Böni RA; Galbraith RA; Drummond GS; Kappas A
Pharmacology; 1993 Nov; 47(5):318-29. PubMed ID: 8265722
[TBL] [Abstract][Full Text] [Related]
31. Characterization of porphyrin heme oxygenase inhibitors.
Vreman HJ; Cipkala DA; Stevenson DK
Can J Physiol Pharmacol; 1996 Mar; 74(3):278-85. PubMed ID: 8773407
[TBL] [Abstract][Full Text] [Related]
32. Cobalt-mesoporphyrin inhibits heme oxygenase activity but it does not induce lipid peroxidation in rat brain membranes during photoirradiation.
Keino H; Banno T; Mimura S; Kashiwamata S
Biol Neonate; 1993; 63(5):285-9. PubMed ID: 8353156
[TBL] [Abstract][Full Text] [Related]
33. [Phototherapy and treatment with phenobarbital in hemolytic disease of newborn due to Rh-incompatibility].
Menzel K; Schambach K; Töpke B
Acta Paediatr Acad Sci Hung; 1974; 15(3-4):333-9. PubMed ID: 4219868
[No Abstract] [Full Text] [Related]
34. Tin-mesoporphyrin for inhibition of heme oxygenase during long-term hyperdynamic porcine endotoxemia.
Nalos M; Vassilev D; Pittner A; Asfar P; Brückner UB; Schneider EM; Georgieff M; Radermacher P; Froeba G
Shock; 2003 Jun; 19(6):526-32. PubMed ID: 12785007
[TBL] [Abstract][Full Text] [Related]
35. Tin(Sn+4)-diiododeuteroporphyrin; an in vitro and in vivo inhibitor of heme oxygenase with substantially reduced photoactive properties.
Drummond GS; Greenbaum NL; Kappas A
J Pharmacol Exp Ther; 1991 Jun; 257(3):1109-13. PubMed ID: 2046022
[TBL] [Abstract][Full Text] [Related]
36. Phototoxicity of tin protoporphyrin, tin mesoporphyrin, and tin diiododeuteroporphyrin under neonatal phototherapy conditions.
Fort FL; Gold J
Pediatrics; 1989 Dec; 84(6):1031-7. PubMed ID: 2531365
[TBL] [Abstract][Full Text] [Related]
37. Intravenous immunoglobulin in ABO and Rh hemolytic diseases of newborn.
Nasseri F; Mamouri GA; Babaei H
Saudi Med J; 2006 Dec; 27(12):1827-30. PubMed ID: 17143357
[TBL] [Abstract][Full Text] [Related]
38. Selection of metalloporphyrin heme oxygenase inhibitors based on potency and photoreactivity.
Vreman HJ; Ekstrand BC; Stevenson DK
Pediatr Res; 1993 Feb; 33(2):195-200. PubMed ID: 8433895
[TBL] [Abstract][Full Text] [Related]
39. Intravenous immunoglobulin in the management of hemolytic disease of the newborn.
Mundy CA
Neonatal Netw; 2005; 24(6):17-24. PubMed ID: 16383181
[TBL] [Abstract][Full Text] [Related]
40. Severe hemolytic disease of the newborn from anti-e.
McAdams RM; Dotzler SA; Winter LW; Kerecman JD
J Perinatol; 2008 Mar; 28(3):230-2. PubMed ID: 18309317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
